VITRAFY LIFE SCIENCES LTD

Vitrafy Life Sciences drops 4.15% as it teases Q1 FY2027 report—learn why Guardion cryo‑tech and LifeChain™ could reshape biotech markets.

Vitrafy Life Sciences shares fell 5.24% to AUD 2.75, with a AUD 217.9 m market cap, while new CFO Jan Gielen takes charge and 5,848 incentive shares are pending ASX approval.